Concepedia

Ellen Weisberg

EW

Statistics

Publications

80

Citations

8.9K

H-Index

44

Active since

1988

Affiliations

Dana-Farber Cancer Institute(Current)

Harvard University

Brigham and Women's Hospital

Novartis (Switzerland)

Chinese Academy of Sciences

Ellen Weisberg is an author at Dana-Farber Cancer Institute specializing in medicine, oncology, and molecular oncology.

ORCID

Publications per year

1988–2022

80

Publications

80

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl

Ellen Weisberg, Paul W. Manley, Werner Breitenstein et al. · Cancer Cell · 2005 · 1.5K citations · Full text

, , +6

Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412

Ellen Weisberg, Christina Boulton, Louise Kelly et al. · Cancer Cell · 2002 · 602 citations · Full text

, , +14

Smad4 and FAST-1 in the assembly of activin-responsive factor

Xin Chen, Ellen Weisberg, Valérie Fridmacher et al. · Nature · 1997 · 568 citations

, , +9

A Chemoproteomic Approach to Query the Degradable Kinome Using a Multi-kinase Degrader

Hai‐Tsang Huang, Dennis Dobrovolsky, Joshiawa Paulk et al. · Cell chemical biology · 2017 · 441 citations · Full text

, , +11

Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL–transformed hematopoietic cell lines

Ellen Weisberg, James D. Griffin · Blood · 2000 · 399 citations

, , +12

1–5 of 80